CANADA LIFE ASSURANCE Co Buys 12,695 Shares of Hologic, Inc. (NASDAQ:HOLX)

CANADA LIFE ASSURANCE Co raised its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 4.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 276,408 shares of the medical equipment provider's stock after buying an additional 12,695 shares during the period. CANADA LIFE ASSURANCE Co owned approximately 0.12% of Hologic worth $19,912,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Benson Investment Management Company Inc. purchased a new position in shares of Hologic during the fourth quarter valued at $4,832,000. Principal Financial Group Inc. grew its stake in Hologic by 0.6% during the 4th quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock valued at $19,547,000 after acquiring an additional 1,606 shares in the last quarter. Clean Yield Group increased its holdings in shares of Hologic by 18.9% in the 4th quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider's stock valued at $3,291,000 after purchasing an additional 7,266 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Hologic by 21.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider's stock valued at $110,700,000 after purchasing an additional 238,222 shares during the period. Finally, Nordea Investment Management AB lifted its position in shares of Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider's stock worth $159,911,000 after purchasing an additional 544,889 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Performance

HOLX stock traded down $0.27 on Friday, reaching $58.02. 1,814,065 shares of the company were exchanged, compared to its average volume of 2,723,866. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm has a market capitalization of $13.02 billion, a PE ratio of 18.30, a PEG ratio of 2.14 and a beta of 0.82. The stock's fifty day moving average price is $61.14 and its 200 day moving average price is $70.22. Hologic, Inc. has a 12 month low of $55.89 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on HOLX. William Blair reiterated an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Evercore ISI cut their price objective on Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a report on Thursday, February 6th. Leerink Partners downgraded Hologic from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Morgan Stanley dropped their target price on Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Finally, Leerink Partnrs cut Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.